{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-115498","form_type":"8-K","ticker":"ACU","cik":"0000002098","company_name":"ACME UNITED CORP","filed_at":"2024-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.634533+00:00","generated_at":"2026-05-30T12:52:53.042833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acme United Q3 net income rises 3% to $2.23M despite 4% sales decline","bullets":["Net income $2.23M ($0.54/diluted) vs $2.15M ($0.58) in Q3 2023; net income up 3%, EPS down 7%.","Net sales $48.2M, down 4% YoY; excluding Camillus/Cuda (sold Nov 2023), sales up 4%.","U.S. segment sales down 6% (ex-div up 3%); Europe up 10% in USD; Canada down 1% (up 2% local).","Bank debt less cash $26.7M at Sep 30, 2024 vs $38.2M a year ago; generated $6.2M free cash flow.","Introduced next-gen industrial first aid kits with patent-pending real-time expiration monitoring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-115498","json":"https://secwatch.observer/filing/0000950170-24-115498.json","markdown":"https://secwatch.observer/filing/0000950170-24-115498.md","text":"https://secwatch.observer/filing/0000950170-24-115498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2098/000095017024115498/0000950170-24-115498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2098/000095017024115498/acu-20241018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T12:52:53.042833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}